MBX Biosciences (MBX) Income from Continuing Operations (2023 - 2026)

MBX Biosciences has disclosed Income from Continuing Operations across 4 years of filings, most recently posting 23517000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 23517000.0, up 1.52% year-over-year; the trailing twelve-month figure through Mar 2026 was 86608000.0 (down 17.89% YoY), and the FY2025 annual result was 86971000.0, down 40.45% from the prior year.
• Income from Continuing Operations came in at 23517000.0 for Q1 2026 at MBX Biosciences, down from 22062000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 8843000.0 in Q4 2023 to a low of 23880000.0 in Q1 2025.
• The 4-year median for Income from Continuing Operations is 18142000.0 (2024), against an average of 17401363.64.
• Across the five-year window, Income from Continuing Operations sank 93.56% in 2025 and increased 1.52% in 2026, its largest moves.
• MBX Biosciences' Income from Continuing Operations stood at 8843000.0 in 2023, then sank by 76.25% to 15586000.0 in 2024, then slumped by 41.55% to 22062000.0 in 2025, then dropped by 6.6% to 23517000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 23517000.0 (Q1 2026), 22062000.0 (Q4 2025), and 21618000.0 (Q3 2025), per Business Quant data.